Market Indices
Sector Heatmap
OKYO — OKYO Pharma Limited Ordinary Shares
NasdaqOKYO Pharma Limited Ordinary Shares
- O
- 1.45
- H
- 1.48
- L
- 1.36
- V
- 33.74K
OKYO — Latest News & Headlines
9 StoriesOKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo! Finance Canada
OKYO Pharma Limited (OKYO) Stock Price, News, Quote & History Yahoo! Finance Canada
A planned trial for corneal nerve pain will enroll about 111 people; OKYO's CEO presents Oct. 8. - Stock Titan
A planned trial for corneal nerve pain will enroll about 111 people; OKYO's CEO presents Oct. 8. Stock Titan
OKYO Pharma Limited (OKYO) stock price, news, quote and history - Yahoo Finance UK
OKYO Pharma Limited (OKYO) stock price, news, quote and history Yahoo Finance UK
A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients. - Stock Titan
A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients. Stock Titan
H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment By Investing.com Investing.com Canada
OKYO Pharma starts Phase 3 trial for neuropathi... - Pluang
OKYO Pharma starts Phase 3 trial for neuropathi... Pluang
A single-dose eye pain treatment is slated for a global trial at OKYO Pharma (OKYO). - Stock Titan
A single-dose eye pain treatment is slated for a global trial at OKYO Pharma (OKYO). Stock Titan
First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. - Stock Titan
First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. Stock Titan
OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain - TipRanks
OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain TipRanks